CDH2

(redirected from N-Cadherin)
Also found in: Acronyms.

CDH2

A gene on chromosome 18q11.2 that encodes a calcium-dependent cell–cell adhesion glycoprotein (cadherin), which is involved in regulating cell–cell adhesions, mobility and proliferation of epithelial cells. CDH2 functions during gastrulation and is required for establishing left-right asymmetry. At certain CNS synapses, presynaptic to postsynaptic adhesion is mediated in part by CDH2; in the hippocampus, it may regulate dendritic spine density.
Mentioned in ?
References in periodicals archive ?
Immunostaining for APC and N-cadherin in control human fetal testis xenografts demonstrated Sertoli cell cytoplasm distribution around the germ cells (Figure 3I,J), similar to that in rats.
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.
Evidence indicates that expression of snail, slug, vimentin, and N-cadherin were induced, whereas the level of E-cadherin was inhibited, suggesting that B[a]P might promote the epithelial-mesenchymal transition (EMT) process.
Furthermore, ginsenoside Rd inhibited the invasion and migration of HepG2 cells in vitro by activating of E-cadherin and vinculin and decreasing the level of N-cadherin.
However, it was not clear from those studies whether interfering with N-cadherin levels would increase survival of animals genetically engineered to develop highly metastatic pancreatic cancer," he noted.
E-Cadherin N-Cadherin P-Cadherin 1 mn + + 2 mn + + 3 mn + + 4 mn + + 5 mn + + 6 mn + + 7 mn + + 8 mn + + 9 mn + - 10 mn + - 11 mn + - 12 mn - + 13 mn - + 14 mn - + 15 mn - - 16 mn - - 17 mn - - 18 mn - - 19 n + + 20 n + + 21 n + - 22 n + - 23 n + - 24 n + - 25 n + - 26 n + - 27 n + - 28 n - - 29 n - - 30 n - - 31 n - - 32 n - - 33 m + + 34 m + - 35 - - -
We will also continue to emphasize our preclinical efforts to develop the scope and depth of our cadherin biotechnology platform by advancing the development of our small molecule N-cadherin antagonists as well as other molecules which affect the function of cadherins.
The first patient was a 62-year-old woman with N-cadherin positive squamous cell cancer of the esophagus with lung metastases.
Adherex has undertaken a study of more than 700 tumor samples to define the prevalence of the molecular marker N-cadherin among a variety of tumor types.
The study, which was launched in May 2005 at the Ottawa Regional Cancer Centre, is designed to evaluate the anti-tumor activity and tolerability of repeated doses of ADH-1 in patients whose tumors express the molecular target N-cadherin.